Literature DB >> 28179462

Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.

Joshua Barton1, Todd A Hardy1, Sean Riminton1, Stephen W Reddel1, Yael Barnett1, Alasdair Coles1, Michael H Barnett2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28179462     DOI： 10.1212/WNL.0000000000003694

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  11 in total

1.  Stabilization Without Rituximab After Disease Activation in an Alemtuzumab-Treated Patient with Multiple Sclerosis and a Literature Overview.

Authors:  Chantal Kahovec; Michael C Levin
Journal:  Int J MS Care       Date:  2019 May-Jun

2.  Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis.

Authors:  Tereza Gabelić; Barbara Barun; Ivan Adamec; Magdalena Krbot Skorić; Mario Habek
Journal:  Hum Vaccin Immunother       Date:  2021-10-20       Impact factor: 4.526

3.  Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy.

Authors:  Francesca Rinaldi; Lisa Federle; Marco Puthenparampil; Paola Perini; Francesca Grassivaro; Paolo Gallo
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-12-13

4.  Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab.

Authors:  Vanessa F Moreira Ferreira; David Meredith; James M Stankiewicz
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-06-26

Review 5.  Safety of Newer Disease Modifying Therapies in Multiple Sclerosis.

Authors:  Georges Jalkh; Rachelle Abi Nahed; Gabrielle Macaron; Mary Rensel
Journal:  Vaccines (Basel)       Date:  2020-12-26

Review 6.  Immunopathology of Tumefactive Demyelinating Lesions-From Idiopathic to Drug-Related Cases.

Authors:  Aigli G Vakrakou; Maria-Evgenia Brinia; Ioanna Svolaki; Theodore Argyrakos; Leonidas Stefanis; Constantinos Kilidireas
Journal:  Front Neurol       Date:  2022-03-15       Impact factor: 4.003

Review 7.  Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management.

Authors:  Nik Krajnc; Gabriel Bsteh; Thomas Berger; Jan Mares; Hans-Peter Hartung
Journal:  Neurotherapeutics       Date:  2022-04-04       Impact factor: 6.088

Review 8.  Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010.

Authors:  Simon Faissner; Ralf Gold
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 6.497

9.  Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world.

Authors:  Tjalf Ziemssen; Katja Thomas
Journal:  Ther Adv Neurol Disord       Date:  2017-08-04       Impact factor: 6.570

10.  Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis.

Authors:  Katja Akgün; Imke Metz; Hagen H Kitzler; Wolfgang Brück; Tjalf Ziemssen
Journal:  Ther Adv Neurol Disord       Date:  2018-03-08       Impact factor: 6.570
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.